Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 12, 2008, Pages 4867-4872

  Kotronen, Anna ^a,b   Lewitt, Moira ^c   Hall, Kerstin ^c   Brismar, Kerstin ^c   Yki Järvinen, Hannele ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN BINDING PROTEIN 1;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FAT CONTENT; FEMALE; HUMAN; INSULIN INFUSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 57349140764     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1245     Document Type: Article

References (29)

1. Kotronen A, Yki-Jarvinen H 2008 Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27-38
2. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group 2005 The metabolic syndrome - a new worldwide definition. Lancet 366:1059-1062
3. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL 2005 Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288:E462-E468
4. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H 2007 Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 92:3490-3497
5. Firth SM, Baxter RC 2002 Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824-854
6. Suikkari AM, Koivisto VA, Rutanen EM, Yki-Jarvinen H, Karonen SL, Seppala M 1988 Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 66:266-272
7. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K 1994 Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 79:872-878
8. Wolk K, Larsson SC, Vessby B, Wolk A, Brismar K 2004 Metabolic, anthropometric, and nutritional factors as predictors of circulating insulin-like growth factor binding protein-1 levels in middle-aged and elderly men. J Clin Endocrinol Metab 89:1879-1884
9. Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A, Sampayo J, Taylor W, Fraser W, White A, Gibson JM 2001 Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 44:333-339
10. van Haeften TW, Zonderland ML, Sabelis LW, van Doorn J 2007 IGF-binding protein-1 levels are related to insulin-mediated glucose disposal and are a potential serum marker of insulin resistance. Response to Maddux et al. Diabetes Care 30:e53; author reply e54
11. Maddux BA, Chan A, De Filippis EA, Mandarino LJ, Goldfine ID 2006 IGF-binding protein-1 levels are related to insulin-mediated glucose disposal and are a potential serum marker of insulin resistance. Diabetes Care 29:1535-1537
12. Liew CF, Wise SD, Yeo KP, Lee KO 2005 Insulin-like growth factor binding protein-1 is independently affected by ethnicity, insulin sensitivity, and leptin in healthy, glucose-tolerant young men. J Clin Endocrinol Metab 90:1483-1488
13. Yki-Jarvinen H, Makimattila S, Utriainen T, Rutanen EM 1995 Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. J Clin Endocrinol Metab 80:3227-3232
14. Rizza RA, Mandarino LJ, Gerich JE 1981 Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 240:E630-E609
15. Kotronen A, Vehkavaara S, Seppala-Lindroos A, Bergholm R, Yki-Jarvinen H 2007 Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 293:E1709-E1715
16. DeFronzo RA, Tobin JD, Andres R 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223
17. Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O 1994 Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 12:487-495
18. Povoa G, Roovete A, Hall K 1984 Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol (Copenh) 107:563-570
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
20. Lewitt MS, Baxter RC 1991 Insulin-like growth factor-binding protein-1: a role in glucose counterregulation? Mol Cell Endocrinol 79:C147-C152
21. Suikkari AM, Koivisto VA, Koistinen R, Seppala M, Yki-Jarvinen H 1989 Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin. J Clin Endocrinol Metab 68:135-140
22. Holly JM 1991 The physiological role of IGFBP-1. Acta Endocrinol (Copenh) 124(Suppl 2):55-62
23. Gay E, Seurin D, Babajko S, Doublier S, Cazillis M, Binoux M 1997 Liver-specific expression of human insulin-like growth factor binding protein-1 in transgenic mice: repercussions on reproduction, ante- and perinatal mortality, and postnatal growth. Endocrinology 138:2937-2947
24. Ezzat VA, Duncan ER, Wheatcroft SB, Kearney MT 2008 The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes Obes Metab 10:198-211
25. Lewitt MS, Hilding A, Ostenson CG, Efendic S, Brismar K, Hall K 2008 Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia 51:1135-1145
26. Hwang DL, Huang SP, Lan WS, Lee PD 2003 Elevated insulin, proinsulin and insulin-like growth factor-binding protein-1 in liver disease. Growth Horm IGF Res 13:316-321
27. Shmueli E, Miell JP, Stewart M, Alberti KG, Record CO 1996 High insulin-like growth factor binding protein 1 levels in cirrhosis: link with insulin resistance. Hepatology 24:127-133
28. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ 2001 Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 7:363-373
29. Petrides AS, Groop LC, Riely CA, DeFronzo RA 1991 Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis. J Clin Invest 88:561-570